For pharmaceuticals, in most countries, aggregation is not a requirement. Changes to regulations are ongoing and many countries continue to add aggregation requirements to help minimize the opportunities for counterfeit operations to gain entry into pharmaceutical distribution networks. Additionally, distributors in the US in particular have been instrumental in pushing manufacturers to aggregate products. When the US DSCSA went into enforcement starting in 2017 (and finalized in 2019), aggregation was not a requirement, however major distributors instructed pharmaceutical companies to aggregate in anticipation of legislation in the coming years. This was very forward thinking, as the US is anticipated to start enforcement of aggregation in 2023. This aids in the process for complete documentation of the chain of custody throughout the supply chain and, for distributors, makes it easier to track down a recalled product or document a potential counterfeit.